Medical devices, healthcare technology and the business of care
PMA approval · P220030

UNIPURE C3F8 Ophthalmic Gas in the UNIFEYE Gas Delivery System, UNIPURE C3F8 Ophthalmic Gas in the UNIPEXY Gas Delivery

Alcon Research, LLC · Decision date Jul 2, 2024

MEDTECHLEDGER EXPLANATIONP220030

What did the FDA approve?

FDA approved UNIPURE C3F8 Ophthalmic Gas in the UNIFEYE Gas Delivery System and UNIPURE C3F8 Ophthalmic Gas in the UNIPEXY Gas Delivery System. Both are indicated for intraocular injection for treatment of uncomplicated retinal detachments. The UNIFEYE version lists associated measures including vitrectomy, fluid/air exchange, transconjunctival and transscleral cryotherapy, laser photocoagulation, and air/gas exchange. The UNIPEXY version lists the same associated measures except air/gas exchange.

The device category is gases used within the eye to place pressure on a detached retina. The product code is LPO, specialty Ophthalmic, and applicant Alcon Research, LLC. The decision date is July 2, 2024. The statement reports the approved indication and associated measures but does not provide safety or effectiveness data.

FDA approval order statement

Approval for UNIPURE C3F8 Ophthalmic Gas in the UNIFEYE Gas Delivery System and UNIPURE C3F8 Ophthalmic Gas in the UNIPEXY Gas Delivery System. The UNIPURE C3F8 Ophthalmic Gas in the UNIFEYE Gas Delivery System is indicated for intraocular injection into the eye for the treatment of uncomplicated retinal detachments. Associated measures used include vitrectomy, fluid/air exchange, transconjunctival and transscleral cryotherapy, laser photocoagulation, and air/gas exchange.The UNIPURE C3F8 Ophthalmic Gas in the UNIPEXY Gas Delivery System is indicated for intraocular injection into the eye for the treatment of uncomplicated retinal detachments. Associated measures used include vitrectomy, fluid/air exchange, transconjunctival and transscleral cryotherapy, and laser photocoagulation.
Regulatory pathway
Original PMA
Clinical specialty
Ophthalmic
Decision date
Jul 2, 2024

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P220030
Regulatory pathway
Premarket approval application
Product code
LPO
Decision code
APPR
Decision date
Jul 2, 2024
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Gases used within eye to place pressure on detached retina.

Product code
LPO
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P220030 received

    Application receipt date recorded by FDA.

  2. P220030 · FDA decision

    APPR

  3. P220030/S012 · Related supplement

    UNIPURE C3F8 Ophthalmic Gas in the UNIFEYE Gas Delivery System

Timeline entries are records held by MedtechLedger for P220030. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P220030

Product / regulatory recordCompanyPathwayDecision dateSource
Alcon Research, LLCPMA supplementSep 30, 2026FDA

Explore the linked device profile

Other records with product code LPO

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Alcon Research, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
20511 Lake Forest Dr., Lake Forest, CA, 92630

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records